NICE turns down two kidney cancer drugs

NICE has issued draft guidance this week turning down two treatments for patients with advanced renal cell carcinoma. Kisplyx (lenvantinib) in combination with everolimus has been turned down for previously treated patients due to uncertainties with the clinical evidence. Fotivda (tivozanib) has been rejected as a first line treatment due to uncertainties on whether the […]

read more

Advances in kidney cancer drug treatments shake up drug choices

The following article provides a comprehensive summary of the changing landscape in the choice of first and second-line drug treatments for advanced kidney cancer, with input from Dr Eric Jonasch, a professor of genitourinary medical oncology at The University of Texas MD Anderson Cancer Center and vice chair of the Kidney Cancer Guidelines Committee for […]

read more

Combination therapy is promising for kidney cancer

In recent years, drugs that target the vascular endothelial growth factor (VEGF) pathway, such as Sutent (sunitinib), Votrient (pazopanib), Nexavar (sorafenib), Inlyta (axitinib) and Avastin (bevacizumab), have been successful at improving the life expectancy of patients with metastatic renal cell carcinoma (RCC). However, for many patients anti-VEGF therapy fails and their disease eventually progresses. Immunotherapies, […]

read more

Eisai has started phase III clinical trial with lenvatinib as a potential first-line treatment for advanced kidney cancer

This week saw the initiation of a global phase III clinical trial of lenvatinib, a multiple receptor tyrosine kinase inhibitor, in combination with everolimus and the anti-PD-1 antibody, pembrolizumab, as a potential first-line treatment for advanced renal cell carcinoma (RCC). The trial is called the CLEAR study, and is being run by the Japanese pharmaceutical company, Eisai. […]

read more

European Commission approves Kisplyx (lenvatinib) for advanced kidney cancer

The European Commission has approved Kisplyx (lenvatinib) for the treatment of people with advanced renal cell carcinoma (RCC). Lenvatinib is a new, more potent tyrosine kinase inhibitor, that is given in combination with everolimus for the treatment of people with advanced RCC following the failure of one prior vascular endothelial growth factor (VEGF) targeted therapy. Lenvatinib […]

read more

Cabozantinib and lenvatinib recommended for approval by the EMA

Cabozantinib (Cabometyx, Ipsen Pharma) and lenvatinib (Kisplyx, Eisai Europe Ltd) have been recommended for approval by the European Medicines Agency (EMA). This will soon give kidney cancer patients in Europe, who are not responding to treatment, two new options to try. The EMA is the European Union agency responsible for the protection of public and animal […]

read more

Lenvatinib plus everolimus improves progression-free survival in renal cell carcinoma

Data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago last week show that lenvatinib (Lenvima) plus everolimus (Afinitor) in kidney cancer significantly improved progression free survival (PFS) compared with everolimus or lenvatinib alone. Patients with metastatic renal cell carcinoma (mRCC) treated with lenvatinib plus everolimus following one prior VEGF targeted therapy […]

read more

FDA approves lenvatinib/everolimus combination for kidney cancer

The FDA has approved the combination of lenvatinib (Lenvima) and everolimus (Afinitor) as a treatment for patients with advanced renal cell carcinoma (RCC) following prior antiangiogeneic therapy, based on survival and response data from a phase II study. In the trial, known as Study 205, the combination of lenvatinib and everolimus reduced the risk of […]

read more
Showing 21 to 28 of 28 results
  TOP